A 52-week double-blind research study evaluating the efficacy and safety of an investigational product called ABBV-154 administered in a subcutaneous injection every other week.
This study may be an option for you if you:
- You are taking glucocorticoids and still experiencing PMR symptoms
- Have previously failed treatment with a TNF antagonist (adalimumab, etanercept, infliximab, certolizumab, golimumab).
Other criteria apply. Please discuss with a staff member to see if this study is
a good fit for you. Qualified participants will receive all study-related care and
study medication or placebo at no cost.